Symbols / EWTX Stock $31.58 +1.12% Edgewise Therapeutics, Inc.
EWTX (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Ratings
Current target
$31.58
Low
$20.00
High
$51.00
Mean
$41.08
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-17 | main | JP Morgan | Overweight → Overweight | $45 |
| 2026-03-17 | reit | Wedbush | Outperform → Outperform | $32 |
| 2026-02-27 | main | Evercore ISI Group | Outperform → Outperform | $45 |
| 2025-11-14 | main | JP Morgan | Overweight → Overweight | $34 |
| 2025-11-07 | main | RBC Capital | Outperform → Outperform | $50 |
| 2025-11-07 | main | Wedbush | Outperform → Outperform | $32 |
| 2025-09-25 | init | Goldman Sachs | — → Neutral | $20 |
| 2025-08-19 | main | JP Morgan | Overweight → Overweight | $30 |
| 2025-08-08 | main | RBC Capital | Outperform → Outperform | $49 |
| 2025-06-30 | init | HC Wainwright & Co. | — → Buy | $42 |
| 2025-06-05 | reit | RBC Capital | Outperform → Outperform | $48 |
| 2025-05-16 | main | JP Morgan | Overweight → Overweight | $40 |
| 2025-05-09 | main | RBC Capital | Outperform → Outperform | $48 |
| 2025-04-21 | main | Wedbush | Outperform → Outperform | $43 |
| 2025-04-03 | main | RBC Capital | Outperform → Outperform | $52 |
| 2025-04-03 | down | Scotiabank | Sector Outperform → Sector Perform | $14 |
| 2025-04-02 | main | Piper Sandler | Overweight → Overweight | $51 |
| 2025-03-07 | init | Scotiabank | — → Sector Outperform | $50 |
| 2025-03-04 | reit | RBC Capital | Outperform → Outperform | $56 |
| 2025-01-22 | init | Stifel | — → Hold | $30 |
- Edgewise Therapeutics (EWTX) Valuation Check After Strong Multi Year Shareholder Returns - simplywall.st Sat, 25 Apr 2026 13
- [ARS] Edgewise Therapeutics, Inc. SEC Filing - Stock Titan hu, 23 Apr 2026 20
- Edgewise Therapeutics (EWTX) Stock: What Investors Should Know | Q4 2025: Profit Disappoints - Stock Market Community - Cổng thông tin điện tử Tỉnh Sơn La hu, 23 Apr 2026 05
- RBC Capital Remains a Buy on Edgewise Therapeutics (EWTX) - The Globe and Mail Sat, 25 Apr 2026 11
- Edgewise Therapeutics CMO Donovan sells $506k in EWTX stock - Investing.com Mon, 30 Mar 2026 07
- Discipline and Rules-Based Execution in EWTX Response - Stock Traders Daily Mon, 20 Apr 2026 21
- Edgewise Therapeutics, Inc. (EWTX) PT Increased to $45 at JPMorgan Amid Optimism on EDG-7500 Pipeline - Yahoo Finance Mon, 30 Mar 2026 07
- Edgewise Therapeutics (NASDAQ:EWTX) Reaches New 12-Month High - Here's What Happened - MarketBeat Mon, 20 Apr 2026 15
- $EWTX stock is down 10% today. Here's what we see in our data. - Quiver Quantitative hu, 18 Dec 2025 08
- Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: A High-Potential Biotech Play with 27% Upside - DirectorsTalk Interviews ue, 17 Feb 2026 08
- Edgewise Therapeutics (EWTX) outlines 2026 director elections, pay and auditor vote - Stock Titan hu, 23 Apr 2026 20
- Edgewise Therapeutics CMO sells $685k in EWTX stock - Investing.com ue, 31 Mar 2026 07
- Director at Edgewise Therapeutics (EWTX) awarded 339 new shares - Stock Titan Fri, 03 Apr 2026 07
- Edgewise gives 4 new hires stock options for 72,000 shares - Stock Titan Wed, 01 Apr 2026 07
- [Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity - Stock Titan hu, 02 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
191.41
+20.51%
|
158.83
+38.89%
|
114.36
+59.59%
|
71.66
|
| Research And Development |
|
151.39
+19.24%
|
126.97
+39.67%
|
90.91
+68.24%
|
54.03
|
| Selling General And Administration |
|
40.02
+25.58%
|
31.87
+35.88%
|
23.45
+33.05%
|
17.63
|
| General And Administrative Expense |
|
40.02
+25.58%
|
31.87
+35.88%
|
23.45
+33.05%
|
17.63
|
| Other Gand A |
|
40.02
+25.58%
|
31.87
+35.88%
|
23.45
+33.05%
|
17.63
|
| Total Expenses |
|
191.41
+20.51%
|
158.83
+38.89%
|
114.36
+59.59%
|
71.66
|
| Operating Income |
|
-191.41
-20.51%
|
-158.83
-38.89%
|
-114.36
-59.59%
|
-71.66
|
| Total Operating Income As Reported |
|
-191.41
-20.51%
|
-158.83
-38.89%
|
-114.36
-59.59%
|
-71.66
|
| EBITDA |
|
-189.14
-20.82%
|
-156.54
-38.99%
|
-112.62
-58.36%
|
-71.12
|
| Normalized EBITDA |
|
-189.14
-20.82%
|
-156.54
-38.99%
|
-112.62
-58.36%
|
-71.12
|
| Reconciled Depreciation |
|
2.27
-1.05%
|
2.29
+32.22%
|
1.73
+221.93%
|
0.54
|
| EBIT |
|
-191.41
-20.51%
|
-158.83
-38.89%
|
-114.36
-59.59%
|
-71.66
|
| Net Income |
|
-167.79
-25.40%
|
-133.81
-33.60%
|
-100.16
-48.08%
|
-67.64
|
| Pretax Income |
|
-167.79
-25.40%
|
-133.81
-33.60%
|
-100.16
-48.08%
|
-67.64
|
| Net Non Operating Interest Income Expense |
|
23.61
-5.63%
|
25.02
+76.26%
|
14.19
+253.26%
|
4.02
|
| Net Interest Income |
|
23.61
-5.63%
|
25.02
+76.26%
|
14.19
+253.26%
|
4.02
|
| Interest Income Non Operating |
|
23.61
-5.63%
|
25.02
+76.26%
|
14.19
+253.26%
|
4.02
|
| Interest Income |
|
23.61
-5.63%
|
25.02
+76.26%
|
14.19
+253.26%
|
4.02
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-167.79
-25.40%
|
-133.81
-33.60%
|
-100.16
-48.08%
|
-67.64
|
| Net Income From Continuing Operation Net Minority Interest |
|
-167.79
-25.40%
|
-133.81
-33.60%
|
-100.16
-48.08%
|
-67.64
|
| Net Income From Continuing And Discontinued Operation |
|
-167.79
-25.40%
|
-133.81
-33.60%
|
-100.16
-48.08%
|
-67.64
|
| Net Income Continuous Operations |
|
-167.79
-25.40%
|
-133.81
-33.60%
|
-100.16
-48.08%
|
-67.64
|
| Normalized Income |
|
-167.79
-25.40%
|
-133.81
-33.60%
|
-100.16
-48.08%
|
-67.64
|
| Net Income Common Stockholders |
|
-167.79
-25.40%
|
-133.81
-33.60%
|
-100.16
-48.08%
|
-67.64
|
| Diluted EPS |
|
—
|
-0.42
+73.25%
|
-1.57
-406.45%
|
-0.31
|
| Basic EPS |
|
—
|
-0.42
+73.25%
|
-1.57
-406.45%
|
-0.31
|
| Basic Average Shares |
|
—
|
94.72
+48.64%
|
63.72
+0.78%
|
63.23
|
| Diluted Average Shares |
|
—
|
94.72
+48.64%
|
63.72
+0.78%
|
63.23
|
| Diluted NI Availto Com Stockholders |
|
-167.79
-25.40%
|
-133.81
-33.60%
|
-100.16
-48.08%
|
-67.64
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
552.60
+13.51%
|
486.82
+43.17%
|
340.04
-7.37%
|
367.10
|
| Current Assets |
|
543.38
+14.28%
|
475.48
+45.41%
|
327.00
-8.40%
|
357.00
|
| Cash Cash Equivalents And Short Term Investments |
|
530.11
+12.75%
|
470.17
+47.67%
|
318.39
-9.53%
|
351.95
|
| Cash And Cash Equivalents |
|
61.15
+46.76%
|
41.67
-51.61%
|
86.10
+291.47%
|
21.99
|
| Other Short Term Investments |
|
468.96
+9.44%
|
428.50
+84.46%
|
232.30
-29.60%
|
329.95
|
| Prepaid Assets |
|
—
|
—
|
—
|
5.05
|
| Other Current Assets |
|
13.28
+149.88%
|
5.31
-38.25%
|
8.60
+70.31%
|
5.05
|
| Total Non Current Assets |
|
9.22
-18.67%
|
11.33
-13.07%
|
13.04
+29.06%
|
10.10
|
| Net PPE |
|
9.22
-16.74%
|
11.07
-12.75%
|
12.69
+28.82%
|
9.85
|
| Gross PPE |
|
15.99
+1.46%
|
15.76
+2.95%
|
15.31
+40.22%
|
10.92
|
| Accumulated Depreciation |
|
-6.77
-44.48%
|
-4.68
-79.09%
|
-2.62
-145.63%
|
-1.06
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.81
+0.00%
|
0.81
+3.73%
|
0.78
+176.87%
|
0.28
|
| Construction In Progress |
|
0.08
|
0.00
-100.00%
|
0.08
-98.91%
|
7.34
|
| Other Properties |
|
5.46
+2.88%
|
5.30
-7.27%
|
5.72
+73.49%
|
3.30
|
| Leases |
|
9.65
+0.00%
|
9.65
+10.52%
|
8.73
|
0.00
|
| Other Non Current Assets |
|
—
|
0.26
-24.71%
|
0.35
+38.65%
|
0.25
|
| Total Liabilities Net Minority Interest |
|
30.35
+9.95%
|
27.60
+30.16%
|
21.20
+4.02%
|
20.39
|
| Current Liabilities |
|
27.37
+14.71%
|
23.86
+42.27%
|
16.77
+1.12%
|
16.59
|
| Payables And Accrued Expenses |
|
13.93
+8.73%
|
12.81
+26.86%
|
10.10
-15.48%
|
11.95
|
| Payables |
|
6.01
+7.65%
|
5.58
+38.61%
|
4.03
-34.07%
|
6.11
|
| Accounts Payable |
|
6.01
+7.65%
|
5.58
+38.61%
|
4.03
-34.07%
|
6.11
|
| Current Accrued Expenses |
|
7.92
+9.56%
|
7.23
+19.07%
|
6.07
+3.96%
|
5.84
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
12.43
+23.61%
|
10.06
+76.58%
|
5.70
+41.25%
|
4.03
|
| Current Debt And Capital Lease Obligation |
|
1.01
+1.81%
|
1.00
+1.63%
|
0.98
+61.18%
|
0.61
|
| Current Capital Lease Obligation |
|
1.01
+1.81%
|
1.00
+1.63%
|
0.98
+61.18%
|
0.61
|
| Total Non Current Liabilities Net Minority Interest |
|
2.98
-20.45%
|
3.74
-15.63%
|
4.43
+16.68%
|
3.80
|
| Long Term Debt And Capital Lease Obligation |
|
2.98
-20.45%
|
3.74
-15.63%
|
4.43
+16.68%
|
3.80
|
| Long Term Capital Lease Obligation |
|
2.98
-20.45%
|
3.74
-15.63%
|
4.43
+16.68%
|
3.80
|
| Other Non Current Liabilities |
|
—
|
—
|
—
|
—
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
—
|
—
|
| Stockholders Equity |
|
522.26
+13.73%
|
459.22
+44.03%
|
318.83
-8.04%
|
346.72
|
| Common Stock Equity |
|
522.26
+13.73%
|
459.22
+44.03%
|
318.83
-8.04%
|
346.72
|
| Capital Stock |
|
0.01
+11.11%
|
0.01
+28.57%
|
0.01
+16.67%
|
0.01
|
| Common Stock |
|
0.01
+11.11%
|
0.01
+28.57%
|
0.01
+16.67%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
106.25
+12.03%
|
94.84
+34.61%
|
70.45
+11.38%
|
63.26
|
| Ordinary Shares Number |
|
106.25
+12.03%
|
94.84
+34.61%
|
70.45
+11.38%
|
63.26
|
| Additional Paid In Capital |
|
1,067.94
+27.54%
|
837.36
+48.60%
|
563.49
+14.38%
|
492.67
|
| Retained Earnings |
|
-546.37
-44.32%
|
-378.58
-54.67%
|
-244.76
-69.27%
|
-144.60
|
| Gains Losses Not Affecting Retained Earnings |
|
0.68
+61.19%
|
0.42
+324.24%
|
0.10
+107.31%
|
-1.35
|
| Other Equity Adjustments |
|
0.68
+61.19%
|
0.42
+324.24%
|
0.10
+107.31%
|
-1.35
|
| Total Equity Gross Minority Interest |
|
522.26
+13.73%
|
459.22
+44.03%
|
318.83
-8.04%
|
346.72
|
| Total Capitalization |
|
522.26
+13.73%
|
459.22
+44.03%
|
318.83
-8.04%
|
346.72
|
| Working Capital |
|
516.01
+14.26%
|
451.62
+45.58%
|
310.23
-8.87%
|
340.41
|
| Invested Capital |
|
522.26
+13.73%
|
459.22
+44.03%
|
318.83
-8.04%
|
346.72
|
| Total Debt |
|
3.99
-15.77%
|
4.74
-12.50%
|
5.41
+22.82%
|
4.41
|
| Capital Lease Obligations |
|
3.99
-15.77%
|
4.74
-12.50%
|
5.41
+22.82%
|
4.41
|
| Net Tangible Assets |
|
522.26
+13.73%
|
459.22
+44.03%
|
318.83
-8.04%
|
346.72
|
| Tangible Book Value |
|
522.26
+13.73%
|
459.22
+44.03%
|
318.83
-8.04%
|
346.72
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-143.82
-31.91%
|
-109.03
-18.58%
|
-91.95
-74.69%
|
-52.63
|
| Cash Flow From Continuing Operating Activities |
|
-143.82
-31.91%
|
-109.03
-18.58%
|
-91.95
-74.69%
|
-52.63
|
| Net Income From Continuing Operations |
|
-167.79
-25.40%
|
-133.81
-33.60%
|
-100.16
-48.08%
|
-67.64
|
| Depreciation Amortization Depletion |
|
2.27
-1.05%
|
2.29
+32.22%
|
1.73
+221.93%
|
0.54
|
| Depreciation |
|
2.27
-1.05%
|
2.29
+32.22%
|
1.73
+221.93%
|
0.54
|
| Depreciation And Amortization |
|
2.27
-1.05%
|
2.29
+32.22%
|
1.73
+221.93%
|
0.54
|
| Stock Based Compensation |
|
34.75
+40.63%
|
24.71
+40.73%
|
17.56
+60.75%
|
10.92
|
| Change In Working Capital |
|
-5.37
-152.03%
|
10.33
+762.05%
|
-1.56
-138.18%
|
4.09
|
| Change In Prepaid Assets |
|
-7.96
-341.89%
|
3.29
+192.65%
|
-3.55
-144.70%
|
-1.45
|
| Change In Payables And Accrued Expense |
|
3.34
-54.01%
|
7.26
+246.02%
|
2.10
-19.90%
|
2.62
|
| Change In Accrued Expense |
|
3.06
-44.46%
|
5.52
+152.12%
|
2.19
-14.86%
|
2.57
|
| Change In Payable |
|
0.27
-84.34%
|
1.74
+1988.04%
|
-0.09
-295.74%
|
0.05
|
| Change In Account Payable |
|
0.27
-84.34%
|
1.74
+1988.04%
|
-0.09
-295.74%
|
0.05
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
1.24
|
| Change In Other Current Liabilities |
|
-0.75
-240.00%
|
-0.22
-111.54%
|
-0.10
-103.56%
|
2.92
|
| Investing Cash Flow |
|
-32.79
+82.24%
|
-184.66
-279.48%
|
102.89
+245.78%
|
-70.58
|
| Cash Flow From Continuing Investing Activities |
|
-32.79
+82.24%
|
-184.66
-279.48%
|
102.89
+245.78%
|
-70.58
|
| Net PPE Purchase And Sale |
|
-0.26
+80.49%
|
-1.31
+77.16%
|
-5.75
-3.59%
|
-5.55
|
| Purchase Of PPE |
|
-0.26
+80.49%
|
-1.31
+77.16%
|
-5.75
-3.59%
|
-5.55
|
| Capital Expenditure |
|
-0.26
+80.49%
|
-1.31
+77.16%
|
-5.75
-3.59%
|
-5.55
|
| Net Investment Purchase And Sale |
|
-32.53
+82.26%
|
-183.34
-268.78%
|
108.63
+267.04%
|
-65.03
|
| Purchase Of Investment |
|
-527.23
-10.52%
|
-477.06
-86.45%
|
-255.87
+12.49%
|
-292.39
|
| Sale Of Investment |
|
494.69
+68.43%
|
293.71
-19.42%
|
364.50
+60.32%
|
227.36
|
| Financing Cash Flow |
|
196.09
-21.33%
|
249.25
+368.82%
|
53.17
-58.99%
|
129.64
|
| Cash Flow From Continuing Financing Activities |
|
196.09
-21.33%
|
249.25
+368.82%
|
53.17
-58.99%
|
129.64
|
| Net Common Stock Issuance |
|
187.36
-21.65%
|
239.15
+354.50%
|
52.62
-59.26%
|
129.16
|
| Proceeds From Stock Option Exercised |
|
8.73
-15.84%
|
10.37
+1354.14%
|
0.71
-1.66%
|
0.72
|
| Net Other Financing Charges |
|
—
|
-0.26
-58.79%
|
-0.17
+34.26%
|
-0.25
|
| Changes In Cash |
|
19.48
+143.85%
|
-44.43
-169.31%
|
64.10
+897.42%
|
6.43
|
| Beginning Cash Position |
|
41.67
-51.61%
|
86.10
+291.47%
|
21.99
+41.29%
|
15.57
|
| End Cash Position |
|
61.15
+46.76%
|
41.67
-51.61%
|
86.10
+291.47%
|
21.99
|
| Free Cash Flow |
|
-144.07
-30.57%
|
-110.34
-12.95%
|
-97.69
-67.91%
|
-58.18
|
| Amortization Of Securities |
|
-7.67
+38.90%
|
-12.54
-31.82%
|
-9.52
-1652.67%
|
-0.54
|
| Common Stock Issuance |
|
187.36
-21.65%
|
239.15
+354.50%
|
52.62
-59.26%
|
129.16
|
| Issuance Of Capital Stock |
|
187.36
-21.65%
|
239.15
+354.50%
|
52.62
-59.26%
|
129.16
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-03 View
- 42026-04-02 View
- 42026-03-31 View
- 42026-03-30 View
- 10-K2026-02-26 View
- 8-K2026-02-26 View
- 42026-01-23 View
- 42026-01-05 View
- 42025-11-24 View
- 8-K2025-11-20 View
- 42025-11-13 View
- 42025-11-13 View
- 42025-11-13 View
- 8-K2025-11-10 View
- 10-Q2025-11-06 View
- 8-K2025-11-06 View
- 42025-10-02 View
- 42025-08-28 View
- 42025-08-14 View
- 42025-08-14 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|